Abstract Number: 0752 • ACR Convergence 2022
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
Background/Purpose: Interleukin-12 (IL-12) and interleukin-23 (IL-23) are two essential cytokins involved in the immune-mediated inflammatory disorders of psoriasis. Anti-IL-12/IL-23 therapy has been developed for the…Abstract Number: 1694 • ACR Convergence 2022
Skin Exposure to UV Light Triggers Podocyte and Distal Tubular Injury, in the Presence of CD177+ Neutrophil Cell Cluster
Background/Purpose: Sensitivity to ultraviolet (UV) light affects ~ 80% of systemic lupus erythematosus (SLE) patients. UV light exposure of lupus skin leads to local and…Abstract Number: 0821 • ACR Convergence 2022
Imiquimod Exaggerates Obesity-associated Adipose Tissue Inflammation in Murine Psoriasis Model
Background/Purpose: Recently, obesity has been known to be associated with psoriasis: obesity has negative effects on the prevalence, severity, and treatment response of psoriasis. High…Abstract Number: 1695 • ACR Convergence 2022
Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease
Background/Purpose: With an incidence of 10 cases per million and lack of animal or ex vivo disease models, dermatomyositis (DM) remains a debilitating disease without…Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…Abstract Number: 1095 • ACR Convergence 2022
A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease
Background/Purpose: A20 (Tnfaip3) levels are reduced in psoriatic plaques and polymorphisms in the TNFAIP3 gene locus are associated with increased risk for both psoriasis and psoriatic…Abstract Number: 2153 • ACR Convergence 2022
Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
Background/Purpose: The last few years have seen the approval of many new agents for the treatment of psoriatic arthritis (PsA) and psoriasis (PSO), resulting in…Abstract Number: 0003 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…Abstract Number: 1150 • ACR Convergence 2022
Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems
Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms driving the vast phenotypic spectrum of psoriatic disease.Methods: To better decipher the cellular…Abstract Number: 2239 • ACR Convergence 2022
Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…Abstract Number: 0061 • ACR Convergence 2021
Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms in the psoriatic arthritis (PsA) joint. This is evidenced by the fact that…Abstract Number: 0356 • ACR Convergence 2021
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
Background/Purpose: Skin disease affects >80% of lupus patients and has been linked to lupus nephritis (LN) flares. We recently found that skin inflammation caused by…Abstract Number: 0513 • ACR Convergence 2021
Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood
Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- Next Page »